444 related articles for article (PubMed ID: 20824725)
1. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.
Pieters R; Hunger SP; Boos J; Rizzari C; Silverman L; Baruchel A; Goekbuget N; Schrappe M; Pui CH
Cancer; 2011 Jan; 117(2):238-49. PubMed ID: 20824725
[TBL] [Abstract][Full Text] [Related]
2. JZP458 closes the asparaginase allergy gap.
Ribera JM
Blood; 2023 Feb; 141(7):685-686. PubMed ID: 36795447
[No Abstract] [Full Text] [Related]
3. Clinical Utility of Pegaspargase in Children, Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia: A Review.
Bender C; Maese L; Carter-Febres M; Verma A
Blood Lymphat Cancer; 2021; 11():25-40. PubMed ID: 33907490
[TBL] [Abstract][Full Text] [Related]
4. Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia.
Dam M; Centanni M; Friberg LE; Centanni D; Karlsson MO; Stensig Lynggaard L; Johannsdottir IM; Wik HS; Malmros J; Vaitkeviciene GE; Griskevicius L; Hallböök H; Jónsson ÓG; Overgaard U; Schmiegelow K; Hansen SN; Heyman M; Albertsen BK
Leukemia; 2024 Apr; 38(4):712-719. PubMed ID: 38287133
[TBL] [Abstract][Full Text] [Related]
5. Determination of l-Asparaginase Activity and Its Therapeutic Monitoring in Children with Hematological Malignancies in a Single Croatian Center.
Lenicek Krleza J; Katusic Bojanac A; Jakovljevic G
Diagnostics (Basel); 2024 Mar; 14(6):. PubMed ID: 38535043
[TBL] [Abstract][Full Text] [Related]
6. Comment on: Desensitization using PEGasparaginase in the era of commercially available Erwinia: A single-institution report on efficacy, cost, and resource utilization.
Tong WH
Pediatr Blood Cancer; 2024 May; 71(5):e30935. PubMed ID: 38433328
[No Abstract] [Full Text] [Related]
7. Desirable L-asparaginases for treating cancer and current research trends.
Tsegaye K; Tsehai BA; Getie B
Front Microbiol; 2024; 15():1269282. PubMed ID: 38591038
[TBL] [Abstract][Full Text] [Related]
8. Correlation of ex vivo and in vivo ammonia production with L-asparaginase biological activity in adults with lymphoid malignancies.
Nakamura T; Oya S; Ozawa H; Maehiro Y; Muta S; Umeda M; Takaki Y; Fukuyama T; Yamasaki Y; Yamaguchi M; Aoyama K; Mouri F; Naito Y; Nagafuji K
Int J Hematol; 2024 Apr; 119(4):426-431. PubMed ID: 38363480
[TBL] [Abstract][Full Text] [Related]
9. Multiple Reactions During Desensitization May Predict Decreased Efficacy of Pegaspargase Chemotherapy.
Gilje EA; Cho C
Ann Allergy Asthma Immunol; 2024 May; ():. PubMed ID: 38762055
[No Abstract] [Full Text] [Related]
10. Optimizing asparaginase therapy for acute lymphoblastic leukemia.
Rizzari C; Conter V; Starý J; Colombini A; Moericke A; Schrappe M
Curr Opin Oncol; 2013 Mar; 25 Suppl 1():S1-9. PubMed ID: 23380829
[TBL] [Abstract][Full Text] [Related]
11. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.
Tong WH; Pieters R; Kaspers GJ; te Loo DM; Bierings MB; van den Bos C; Kollen WJ; Hop WC; Lanvers-Kaminsky C; Relling MV; Tissing WJ; van der Sluis IM
Blood; 2014 Mar; 123(13):2026-33. PubMed ID: 24449211
[TBL] [Abstract][Full Text] [Related]
12. Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
Salzer WL; Asselin BL; Plourde PV; Corn T; Hunger SP
Ann N Y Acad Sci; 2014 Nov; 1329():81-92. PubMed ID: 25098829
[TBL] [Abstract][Full Text] [Related]
13. Use of L-asparaginase in childhood ALL.
Müller HJ; Boos J
Crit Rev Oncol Hematol; 1998 Aug; 28(2):97-113. PubMed ID: 9768345
[TBL] [Abstract][Full Text] [Related]
14. How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia.
Burke MJ
Future Oncol; 2014 Dec; 10(16):2615-27. PubMed ID: 24983955
[TBL] [Abstract][Full Text] [Related]
15. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel.
Stock W; Douer D; DeAngelo DJ; Arellano M; Advani A; Damon L; Kovacsovics T; Litzow M; Rytting M; Borthakur G; Bleyer A
Leuk Lymphoma; 2011 Dec; 52(12):2237-53. PubMed ID: 21827361
[TBL] [Abstract][Full Text] [Related]
16. Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia.
Andrade AF; Borges KS; Silveira VS
Clin Med Insights Oncol; 2014; 8():95-100. PubMed ID: 25210485
[TBL] [Abstract][Full Text] [Related]
17. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
Plourde PV; Jeha S; Hijiya N; Keller FG; Silverman LB; Rheingold SR; Dreyer ZE; Dahl GV; Mercedes T; Lai C; Corn T
Pediatr Blood Cancer; 2014 Jul; 61(7):1232-8. PubMed ID: 24436152
[TBL] [Abstract][Full Text] [Related]
18. Comparative pharmacokinetic studies of three asparaginase preparations.
Asselin BL; Whitin JC; Coppola DJ; Rupp IP; Sallan SE; Cohen HJ
J Clin Oncol; 1993 Sep; 11(9):1780-6. PubMed ID: 8355045
[TBL] [Abstract][Full Text] [Related]
19. Recent developments in L-asparaginase discovery and its potential as anticancer agent.
Shrivastava A; Khan AA; Khurshid M; Kalam MA; Jain SK; Singhal PK
Crit Rev Oncol Hematol; 2016 Apr; 100():1-10. PubMed ID: 25630663
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
